Noradrenergic and serotonergic involvement in brief shock-induced analgesia in rats

Four experiments were performed to investigate the effects of different techniques causing noradrenergic and serotonergic depletions in the brain and spinal cord on brief shock-induced analgesia. Newborn pups were administered N-2-choloroethyl-N-ethyl-2-bromobenzylamine systemically (2 x 50 mg/kg, ip) and 6-hydroxydopamine administered either systemically (100 micrograms/g, sc) or directly (8 micrograms in 1 microliter, bilaterally) into the locus coeruleus region, or intrathecally (20 micrograms in 10 microliter) into the lumbar subarachnoidal space, caused notable and consistent attenuations of the analgesia caused by brief shock. These treatments reduced noradrenaline concentrations in the spinal cord drastically. A potentiation of brief shock-induced analgesia was caused by the administration of p-chlorophenyl-alanine, whereas administration of 5,7-dihydroxytryptamine, into the nucleus raphe magnus or intrathecally into the subarachnoidal space, produced attenuation of the analgesic effect. Biochemical analyses revealed marked 5-hydroxytryptamine depletions in the spinal cord. The present findings are discussed with regard to the role of spinal noradrenaline and 5-hydroxytryptamine involvement in brief shock-induced analgesia and in reactions to stressful events.     

Adaptive changes in alpha-2 adrenoceptor mediated responses: analgesia, hypothermia and hypoactivity

The acute effects of the alpha-2 adrenoceptor agonists, clonidine and guanfacine, upon antinociception, hypothermia and motor activity were compared under conditions of receptor antagonism, denervation, and chronic administration of a tricyclic antidepressant compound. The analgesic actions of clonidine and guanfacine were antagonised by idazoxan, an alpha-2 receptor antagonist, but potentiated by pretreatment with the noradrenaline neurotoxin DSP4, and attenuated by chronic treatment with desipramine (DMI). Clonidine- and guanfacine-induced hypothermia was antagonised by idazoxan, potentiated by prior treatment with DSP4 and attenuated by chronic administration with DMI. Both clonidine and guanfacine produced decreases in motor activity that were attenuated by idazoxan but unaffected by prior DSP-4 treatment. Chronic DMI administration also attenuated clonidine-induced hypoactivity but potentiated guanfacine-induced hypoactivity. These diverse results describe both similar and differential adaptive mechanisms modulating the functional effect of alpha-2 receptor systems in the central nervous system.     

Modulation of glutamate receptors by phencyclidine and glycine in the rat cerebellum: cGMP increase in vivo

In rats receiving N-methyl-D-aspartate (NMDA) intraventricularly or intracisternally the cerebellar cyclic guanosine monophosphate (cGMP) content increases in a dose-related manner. This response was used to study phencyclidine (PCP) and glycine interactions with the glutamate receptor subtype stimulated by NMDA. The increase of cGMP elicited by NMDA was inhibited by PCP and potentiated by glycine. Moreover, 2-amino-5-phosphonovalerate (APV) abolished the NMDA response. Since the increase in cerebellar cGMP induced by kainate, a synthetic agonist of another glutamate receptor subtype, was not modified by APV, the specificity of its action on NMDA response was confirmed. The increase of cerebellar cGMP content elicited by glycine was inhibited by PCP and APV but not by strychnine. Binding studies failed to demonstrate an apparent competitive interaction between PCP, glycine and NMDA. This suggests that the observed interaction is not of the isosteric type. The present results provide evidence that glycine, in vivo, acting at strychnine-insensitive recognition sites modulates allosterically in a positive manner the function of NMDA-sensitive glutamate receptors.     

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine - searching for the connections

β-amyloid (Aβ) is widely accepted to be one of the major pathomechanisms underlying Alzheimer's disease (AD), although there is presently lively debate regarding the relative roles of particular species/forms of this peptide. Most recent evidence indicates that soluble oligomers rather than plaques are the major cause of synaptic dysfunction and ultimately neurodegeneration. Soluble oligomeric Aβ has been shown to interact with several proteins, for example glutamatergic receptors of the NMDA type and proteins responsible for maintaining glutamate homeostasis such as uptake and release. As NMDA receptors are critically involved in neuronal plasticity including learning and memory, we felt that it would be valuable to provide an up to date review of the evidence connecting Aβ to these receptors and related neuronal plasticity. Strong support for the clinical relevance of such interactions is provided by the NMDA receptor antagonist memantine. This substance is the only NMDA receptor antagonist used clinically in the treatment of AD and therefore offers an excellent tool to facilitate translational extrapolations from in vitro studies through in vivo animal experiments to its ultimate clinical utility.     

Some behavioral effects of microinjections of noradrenaline and serotonin into the amygdaloid body of the rat brain

The effects of microinjections of noradrenaline (NA) and serotonin (5HT) into the basomedial part of the amygdaloid body (BM AB) on various forms of behavior were studied in rats. NA as well as 5HT administered to the BM AB had dose-related and general inhibitory influence on the rats' behavior in the open field test. The reactivity of rats to pain (tail compression) was attenuated by 5HT injections. The effect of NA in this test was less clear, though some inhibitory tendency was also present. Pretrial injections of NA (40 micrograms) and 5HT (40 micrograms) significantly impaired the retention of a passive avoidance reaction. NA injections also produced some disinhibitory effects on shock-suppressed drinking in the conflict test. The effects of intra-amygdalar administration of NA and 5HT on open field behavior were potentiated by pretreatment of rats with nialamide, a monoaminooxidase inhibitor. The results are discussed in terms of an involvement of the amydalar NA and 5HT in the regulation of animal behavior.     

Some aspects of stress and depression

1. The role of stress in depressive illness is discussed together with utility of the "learned helplessness" model and some neuropharmacological correlates of uncontrollable shock. 2. Similarities and differences between chronic antidepressant treatment and chronic stress treatment regimes are reviewed. 3. Finally the role of adaptive process in stress on antidepressant treatments is discussed.     

Analgesic effects of mGlu1 and mGlu5 receptor antagonists in the rat formalin test

mGlu1 and mGlu5 receptors have been implicated in pain associated with inflammation. In the present study, the formalin test was used to measure sustained pain with components of tissue injury. The aims of the present study were to assess: (i) the role of mGlu1 and mGlu5 receptors in inflammatory pain using selective antagonist EMQMCM, 1.25-5 mg/kg, as the mGlu1 receptor antagonist, and MPEP or MTEP, 2.5-10 mg/kg, as mGlu5 receptor antagonist; (ii) the possible interaction between mGlu1 and mGlu5 receptor antagonists and morphine; and (iii) whether tolerance develops to the analgesic effects of these antagonists after prolonged treatment. EMQMCM, MTEP and MPEP significantly reduced the manifestation of both phases of formalin response. However, all these mGlu receptor antagonists did not affect the withdrawal latencies in a model of acute pain (Hargreaves test), which has a different underlying mechanism. In the present study, the suppressive effect on formalin-induced pain behaviour was much stronger when mGlu1 and mGlu5 receptor antagonists were co-injected compared to administration of a single antagonist, but this effect was not seen when mGlu receptor antagonist was co-administered with morphine. This is in contrast to the pronounced inhibitory effects after co-treatment with morphine and the uncompetitive NMDA receptor antagonist memantine. The present study also provides the first direct in vivo evidence that prolonged administration of MTEP (5 mg/kg) over 7 days leads to the development of tolerance to its antinociceptive effects. Such tolerance was not observed when EMQMCM (5 mg/kg) was administered in the same manner. In conclusion, these results provide additional arguments for the role of group I mGlu receptors in pain with inflammatory conditions.